ACADIA Pharmaceuticals (NASDAQ:ACAD) : The consensus on ACADIA Pharmaceuticals (NASDAQ:ACAD) based on 7 analyst recommendation on the company stock is 1.57, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
ACADIA Pharmaceuticals (NASDAQ:ACAD) : 9 investment research analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD) have an average price target of $46.44 for the near short term. The highest target price given by the Brokerage Firm to the stock is $55 and the lowest target is $35 for the short term. Analysts expect the variance to be within $6.65 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Bank of America downgrades its ratings on ACADIA Pharmaceuticals (NASDAQ:ACAD). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on June 22, 2016.
ACADIA Pharmaceuticals (NASDAQ:ACAD): stock turned positive on Tuesday. Though the stock opened at $30.98, the bulls momentum made the stock top out at $31.87 level for the day. The stock recorded a low of $30.6842 and closed the trading day at $31.66, in the green by 4.49%. The total traded volume for the day was 2,193,647. The stock had closed at $30.3 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (EVP AND GC) of Acadia Pharmaceuticals Inc, Baity Glenn had sold 7,000 shares worth of $145,600 in a transaction dated March 2, 2016. In this transaction, 7,000 shares were sold at $20.8 per share.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.